Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma - 28/05/22
Highlight |
• | Camrelizumab combined with TACE treatment significantly improve the liver function of patients with massive HCC |
• | improve the treatment effect, which is worthy of clinical promotion. |
• | Camrelizumab combined with TACE reduce the levels of AFP, CEA and CA19-9 in patients with massive HCC |
Abstract |
Objective |
To investigate the efficacy of camrelizumab plus transarterial chemoembolization (TACE) on massive hepatocellular carcinoma (HCC) patients.
Methods |
A total of 92 cases with massive HCC from October 2019 to January 2021 were prospectively enrolled and randomly divided into the study group (n = 46) and the control group (n = 46). The control group received TACE while the study group were treated with camrelizumab plus TACE. The primary end points were clinical efficacy and adverse events. And the secondary end points were liver function, and alpha fetoprotein (AFP), carcino-embryonic antigen (CEA), carbohydrate antigen 19–9 (CA19–9) levels before and after treatment.
Results |
All participants were followed-up for 7 to 24 months, with a median of 12 months. Patients in the study group received TACE for 1–3 times, with an average of (2.01 ± 0.09) times, while patients in the control group receive TACE for 2–4 times, with an average of (3.78 ± 0.12) times, and the control group received significantly more TACEs (χ2 = 5.518, P = 0.019). During the follow-up, the response rate and disease control rate of the study group were significantly higher than those of the control group (χ2 = 5.518, P = 0.019; χ2 = 4.467, P = 0.041). Before treatment, the levels of total bilirubin (TBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alpha-fetoprotein (AFP), CEA, and CA19–9 were comparable between the groups (P > 0.05). After treatment, the levels of TBIL, ALT, AST, AFP, CEA, and CA19–9 decreased, and the above indicators in the study group were significantly lower than those in the control group (P < 0.05). All patients showed transient liver damage, vomiting, nausea, fever and abdominal pain after surgery, and their symptoms were relieved after symptomatic treatment. Adverse events occurred in 9 cases in the study group, and 3 cases in the control group (χ2 = 3.419, P = 0.064).
Conclusion |
Compared with TACE alone, camrelizumab plus TACE treatment can significantly improve the liver function of patients with massive HCC and enhance the treatment effect, which is worthy of clinical promotion.
Le texte complet de cet article est disponible en PDF.Keywords : Camrelizumab, Transarterial chemoembolization, Massive hepatocellular carcinoma, Liver function Abbreviations Afp: alpha fetal protein, Alt: alanine aminotransferase, Ast: aspartate aminotransferase, Cea: carcino-embryonic antigen, Cnlc: Chinese liver cancer, Ca19-9: carbohydrate antigen 19-9, Dcr: Disease control rate, Hcc: hepatocellular carcinoma, Mrecist: modified Response Evaluation Criteria in Solid Tumors, Pfs: Progression-free survival, Pr: Partial response, Pd: Progressive disease, Rr: Response rate, Sd: Stable disease, Tace: transarterial chemoembolization, Tbil: total bilirubin
Plan
Vol 46 - N° 4
Article 101851- avril 2022 Retour au numéro
Article précédent
- Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners
- Clémence M. Canivet, Sarra Smati, Adrien Lannes, Julie Brisseau, Louise Judon, Marion Le Roch, Bertrand Cariou, William Bellanger, Bruno Guerci, Jérôme Boursier
- Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model
- Hua Wang, Xue He, Dong Fang, Xian Wang, Jing Guan, Zhen-Wang Shi, Xi Chen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?